These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 33435774)

  • 1. COVID-19 vaccine: where are we now and where should we go?
    Soleimanpour S; Yaghoubi A
    Expert Rev Vaccines; 2021 Jan; 20(1):23-44. PubMed ID: 33435774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
    Rohilla S
    Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.
    Zinatizadeh MR; Zarandi PK; Zinatizadeh M; Yousefi MH; Amani J; Rezaei N
    Biomed Pharmacother; 2022 Feb; 146():112527. PubMed ID: 34906769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.
    Khehra N; Padda I; Jaferi U; Atwal H; Narain S; Parmar MS
    AAPS PharmSciTech; 2021 Jun; 22(5):172. PubMed ID: 34100150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
    Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
    Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.
    Begum J; Mir NA; Dev K; Buyamayum B; Wani MY; Raza M
    Transbound Emerg Dis; 2021 May; 68(3):1111-1124. PubMed ID: 32815655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 2020 race towards SARS-CoV-2 specific vaccines.
    Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D
    Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 reinfection and implications for vaccine development.
    Nainu F; Abidin RS; Bahar MA; Frediansyah A; Emran TB; Rabaan AA; Dhama K; Harapan H
    Hum Vaccin Immunother; 2020 Dec; 16(12):3061-3073. PubMed ID: 33393854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.
    Chauhan N; Soni S; Gupta A; Aslam M; Jain U
    J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19: Coronavirus Vaccine Development Updates.
    Zhao J; Zhao S; Ou J; Zhang J; Lan W; Guan W; Wu X; Yan Y; Zhao W; Wu J; Chodosh J; Zhang Q
    Front Immunol; 2020; 11():602256. PubMed ID: 33424848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2.
    Bilal M; Iqbal HMN
    Hum Vaccin Immunother; 2020 Dec; 16(12):3034-3042. PubMed ID: 32845742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.